TeraWulf Announces Mandatory Conversion Date for Series A Convertible Preferred Stock GlobeNewswire November 25, 2025 EASTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), announced today that it has exercised its right to cause the mandatory conversion of all outstanding shares of its Series A Convertible Preferred Stock […]

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader GlobeNewswire November 25, 2025 Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire November 25, 2025 WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference GlobeNewswire November 25, 2025 WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual

Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500(TM) Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024 GlobeNewswire November 25, 2025 WEST LAFAYETTE, Ind., Nov. 25, 2025 (GLOBE NEWSWIRE) — Inotiv

Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference GlobeNewswire November 25, 2025 CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) — Foghorn(R) Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program GlobeNewswire November 25, 2025 First publicly listed company to actively investigate psilocybin's potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health

OTC Markets Group Welcomes Compass Group PLC to OTCQX GlobeNewswire November 25, 2025 NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Compass Group PLC (LSE: CPG; OTCQX: CMPGY; CMPGF), a global leader in food services, has

Intchains Group to Participate in Two Upcoming Investor Conferences GlobeNewswire November 25, 2025 SINGAPORE, Nov. 25, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company engaged in the provision of altcoin mining products, strategic acquisition and holding of Ethereum-based cryptocurrencies, and active development of innovative Web3 applications, today announced

Cronos Launches Premium Lord Jones Live Resin Fusions(TM) in Canada GlobeNewswire November 25, 2025 TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced is expanding its portfolio for its Lord Jones(R) brand with new innovations designed to enhance its